REVIEW article

Front. Immunol.

Sec. Immunological Tolerance and Regulation

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1613719

Tumor necrosis factor receptor 2 in allergen tolerance: a perspective view

Provisionally accepted
  • 1University College London, London, England, United Kingdom
  • 2Department of Infection and Immunity, Luxembourg Institute of Health, Luxembourg, Luxembourg

The final, formatted version of the article will be published soon.

Central and peripheral tolerance are key to maintain immune homeostasis. Imbalance of these processes often leads to diseases such as allergy, cancer or autoimmune disorders. During the immune response to allergens, several regulatory immune cells play a role in the development of peripheral tolerance and maintenance of homeostasis by inhibiting the development of CD4 + type 2 helper T cells, impairing the production of pro-allergenic cytokines, reducing the activation of effector cells driving allergic inflammation and generating allergen-neutralising antibodies. However, the precise mechanisms of how peripheral immune tolerance is effectively maintained in healthy people, but not in allergic patients are still not well understood. Immune checkpoints have recently been proposed as critical molecular pathways across diseases for understanding how the immune system maintains homeostasis in many pathologies such as cancer, type 1 diabetes, multiple sclerosis, Crohn's disease and allergy, among others. Particularly in the context of allergy, in-depth studies on immune checkpoint pathways might lead to emerging therapeutic targets. Tumor necrosis factor receptor 2 (TNFR2) is a crucial protein involved in promotion, expansion and maintenance of immune tolerance, being suggested as a key target for the treatment of several immune-based diseases including allergy. Here, we review the involvement of TNFR2 in allergic inflammation and allergen tolerance, its structural properties, signaling pathways, and importance for immune tolerance as a common mechanism, with the focus on possible implications for novel immunomodulatory treatments of allergic diseases.

Keywords: Allergen tolerance, Allergen specific immunotherapy (AIT), TNFR2, Peripheral Tolerance, non-canonical NF-ĸB signaling, TNF receptor, Immune checkpoint

Received: 17 Apr 2025; Accepted: 03 Jun 2025.

Copyright: © 2025 Montamat, Luiz Bazon, Demczuk, Leonard and Ollert. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Markus W. Ollert, Department of Infection and Immunity, Luxembourg Institute of Health, Luxembourg, Luxembourg

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.